VSTM earnings analysis
What we found in VSTM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Verastem reported total revenue of $18.7 million for the first quarter of 2026 due to strong commercial sales of AVMAPKI FAKZYNJA CO-PACK, marking a significant increase from $0 in the same quarter last year. The net loss improved to $36.6 million from $52.1 million year-over-year, reflecting a decline in operating expenses as the commercial operations continue to ramp up.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Product Revenue Surge
- Verastem's product revenue reached $18.7 million in Q1 2026, a substantial increase from $0 in Q1 2025.
- Gross Margin Achievement
- Gross margin percentage was approximately 85.1%, aligning with previous periods, indicating consistent cost management.
- Net Loss Reduction
- Net loss decreased to $36.6 million in Q1 2026 compared to $52.1 million in Q1 2025, improving 30% year-over-year.
- Increased Cash Position
- Total cash, cash equivalents, and investments totaled $181.7 million as of March 31, 2026.
- Operational Cash Flow Improvement
- Cash used in operating activities was $52.1 million, compared to $38.7 million for the same period in 2025, indicating a controlled spend despite growth.
- Tariff Consideration
- Change in fair value of the warrant liability led to a $9.3 million income in Q1 2026, significantly higher than a $2.4 million expense in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity Concerns
- Management highlighted substantial doubt about continuing operations without additional financing, especially after increasing clinical trial expenses.
- Dependence on AVMAPKI FAKZYNJA CO-PACK
- Revenue is heavily reliant on the commercial success of AVMAPKI, with no backup product revenue currently.
- Regulatory Risks
- There is heightened risk associated with ongoing clinical trials, potentially delaying key product approvals.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.47
- Gross margin
- 85.1%
- Segment
- Total Revenue: $18.7 million from product sales
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · March 4, 2026
- Verastem transitioned to a commercial-stage oncology company in 2025 after FDA accelerated approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025 and recognized $30.9 million in net product revenue in the first seven…
- 10-Q · May 13, 2025
- Verastem reported a quarterly loss of $52.1 million for Q1 2025, with revenues remaining at zero, which marks a significant decline compared to a loss of $33.9 million in the prior year. The company’s operating expenses…
- 10-K · March 20, 2025
- Verastem (VSTM) positions itself as a late‑stage development biotech focused on RAS/MAPK pathway small molecules, principally the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib, with combination programs…
- 10-Q · November 8, 2023
- Verastem reported zero revenue for the three months ended September 30, 2023 and a Q3 net loss of $20.0M (‑$0.75 per share), with higher R&D and SG&A driving operating expenses of $21.3M. Cash and short-term investments…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VSTM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever